ZL-2306(nirapairb)

DRUG2 trials

Sponsors

Zai Lab (Shanghai) Co., Ltd.

Conditions

Extensive-stage Small Cell Lung CancerPlatinum-sensitive Relapsed Ovarian Cancer

Phase 3

A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer

TerminatedNCT03516084

Zai Lab (Shanghai) Co., Ltd.Extensive-stage Small Cell Lung Cancer

Start: 2018-08-20End: 2020-03-20Updated: 2020-12-21

Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient

Zai Lab (Shanghai) Co., Ltd.Platinum-sensitive Relapsed Ovarian Cancer

Start: 2017-06-08End: 2024-08-24Updated: 2023-04-13

Related Papers

Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial.

2024-05-0710 citations

34 Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 trial

2024-03-012 citations

35O Overall survival of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer adjusted for subsequent PARPi use in placebo group: Results from an ad hoc interim analysis for the phase III NORA study

ESMO Open2023-02-011 citations

O017/#15 Efficacy and safety of niraparib maintenance treatment in platinum-sensitive recurrent ovarian cancer after shorter or longer chemotherapy: a post hoc subgroup analysis

2021-11-01

29 Dose modification for Chinese patients on niraparib maintenance treatment for platinum-sensitive recurrent ovarian cancer: A <i>post hoc</i> analysis

Ovarian cancer2021-10-013 citations

Niraparib efficacy and safety in patients with <i>BRCA</i> mutated (<i>BRCA</i>m) ovarian cancer: Results from three phase 3 niraparib trials.

Journal of Clinical Oncology2021-05-202 citations

Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.

Journal of Clinical Oncology2021-05-201 citations

Efficacy of niraparib maintenance therapy in Chinese women with platinum-sensitive recurrent ovarian cancer with and without secondary cytoreductive surgery: Results from the NORA trial.

Journal of Clinical Oncology2021-05-20

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial<sup>☆</sup>.

2021-01-14142 citations